Global Neurodegenerative Disease Treatment Market 2023 by Company, Regions, Type and Application, Forecast to 2029
Neurodegenerative diseases largely refer to incremental damage to nerve cells in different parts of the body. These ailments, including Alzheimer’s disease, Parkinson’s disease, ADHD, and ALS, can result in loss of memory and cognitive control. While cures for such conditions are very limited, over the years, the pharmaceutical industry has released a number of treatment offerings to minimize the symptoms of neurodegenerative diseases.
According to our (Global Info Research) latest study, the global Neurodegenerative Disease Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Neurodegenerative Disease Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neurodegenerative Disease Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurodegenerative Disease Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurodegenerative Disease Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neurodegenerative Disease Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Chapter 1, to describe Neurodegenerative Disease Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurodegenerative Disease Treatment, with revenue, gross margin and global market share of Neurodegenerative Disease Treatment from 2018 to 2023.
Chapter 3, the Neurodegenerative Disease Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neurodegenerative Disease Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurodegenerative Disease Treatment.
Chapter 13, to describe Neurodegenerative Disease Treatment research findings and conclusion.
According to our (Global Info Research) latest study, the global Neurodegenerative Disease Treatment market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Neurodegenerative Disease Treatment market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Neurodegenerative Disease Treatment market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Disease Treatment market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurodegenerative Disease Treatment
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurodegenerative Disease Treatment market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Allergan plc, Bayer AG, F. Hoffmann La-Roche Ltd., GlaxoSmithKline plc and Johnson & Johnson, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
Neurodegenerative Disease Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Neurotransmitter Agents
- Neuroprotective Agents
- Biologics
- Others
- Multiple Sclerosis [MS]
- Alzheimer’s Disease
- Parkinson's Disease
- Acute Migraine
- Autism
- Narcolepsy
- Amyotrophic Lateral Sclerosis [ALS]
- Attention Deficit Hyperactivity Disorder [ADHD]
- Spinal Muscular Atrophy
- Huntington's Disease
- Allergan plc
- Bayer AG
- F. Hoffmann La-Roche Ltd.
- GlaxoSmithKline plc
- Johnson & Johnson
- Merck KGaA
- Novartis AG
- Pfizer, Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Neurodegenerative Disease Treatment product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurodegenerative Disease Treatment, with revenue, gross margin and global market share of Neurodegenerative Disease Treatment from 2018 to 2023.
Chapter 3, the Neurodegenerative Disease Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neurodegenerative Disease Treatment market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurodegenerative Disease Treatment.
Chapter 13, to describe Neurodegenerative Disease Treatment research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Neurodegenerative Disease Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neurodegenerative Disease Treatment by Type
1.3.1 Overview: Global Neurodegenerative Disease Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Neurodegenerative Disease Treatment Consumption Value Market Share by Type in 2022
1.3.3 Neurotransmitter Agents
1.3.4 Neuroprotective Agents
1.3.5 Biologics
1.3.6 Others
1.4 Global Neurodegenerative Disease Treatment Market by Application
1.4.1 Overview: Global Neurodegenerative Disease Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Multiple Sclerosis [MS]
1.4.3 Alzheimer’s Disease
1.4.4 Parkinson's Disease
1.4.5 Acute Migraine
1.4.6 Autism
1.4.7 Narcolepsy
1.4.8 Amyotrophic Lateral Sclerosis [ALS]
1.4.9 Attention Deficit Hyperactivity Disorder [ADHD]
1.4.10 Spinal Muscular Atrophy
1.4.11 Huntington's Disease
1.5 Global Neurodegenerative Disease Treatment Market Size & Forecast
1.6 Global Neurodegenerative Disease Treatment Market Size and Forecast by Region
1.6.1 Global Neurodegenerative Disease Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Neurodegenerative Disease Treatment Market Size by Region, (2018-2029)
1.6.3 North America Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Allergan plc
2.1.1 Allergan plc Details
2.1.2 Allergan plc Major Business
2.1.3 Allergan plc Neurodegenerative Disease Treatment Product and Solutions
2.1.4 Allergan plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Allergan plc Recent Developments and Future Plans
2.2 Bayer AG
2.2.1 Bayer AG Details
2.2.2 Bayer AG Major Business
2.2.3 Bayer AG Neurodegenerative Disease Treatment Product and Solutions
2.2.4 Bayer AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bayer AG Recent Developments and Future Plans
2.3 F. Hoffmann La-Roche Ltd.
2.3.1 F. Hoffmann La-Roche Ltd. Details
2.3.2 F. Hoffmann La-Roche Ltd. Major Business
2.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product and Solutions
2.3.4 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 F. Hoffmann La-Roche Ltd. Recent Developments and Future Plans
2.4 GlaxoSmithKline plc
2.4.1 GlaxoSmithKline plc Details
2.4.2 GlaxoSmithKline plc Major Business
2.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Product and Solutions
2.4.4 GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Product and Solutions
2.5.4 Johnson & Johnson Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck KGaA
2.6.1 Merck KGaA Details
2.6.2 Merck KGaA Major Business
2.6.3 Merck KGaA Neurodegenerative Disease Treatment Product and Solutions
2.6.4 Merck KGaA Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Merck KGaA Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Neurodegenerative Disease Treatment Product and Solutions
2.7.4 Novartis AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Pfizer, Inc.
2.8.1 Pfizer, Inc. Details
2.8.2 Pfizer, Inc. Major Business
2.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Product and Solutions
2.8.4 Pfizer, Inc. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pfizer, Inc. Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Neurodegenerative Disease Treatment Product and Solutions
2.9.4 Sanofi Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sanofi Recent Developments and Future Plans
2.10 Teva Pharmaceutical Industries Ltd.
2.10.1 Teva Pharmaceutical Industries Ltd. Details
2.10.2 Teva Pharmaceutical Industries Ltd. Major Business
2.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product and Solutions
2.10.4 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neurodegenerative Disease Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Neurodegenerative Disease Treatment by Company Revenue
3.2.2 Top 3 Neurodegenerative Disease Treatment Players Market Share in 2022
3.2.3 Top 6 Neurodegenerative Disease Treatment Players Market Share in 2022
3.3 Neurodegenerative Disease Treatment Market: Overall Company Footprint Analysis
3.3.1 Neurodegenerative Disease Treatment Market: Region Footprint
3.3.2 Neurodegenerative Disease Treatment Market: Company Product Type Footprint
3.3.3 Neurodegenerative Disease Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neurodegenerative Disease Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Neurodegenerative Disease Treatment Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Neurodegenerative Disease Treatment Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
6.2 North America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
6.3 North America Neurodegenerative Disease Treatment Market Size by Country
6.3.1 North America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
7.2 Europe Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
7.3 Europe Neurodegenerative Disease Treatment Market Size by Country
7.3.1 Europe Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.3 France Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region
8.3.1 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2018-2029)
8.3.2 China Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.5 India Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
9.2 South America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
9.3 South America Neurodegenerative Disease Treatment Market Size by Country
9.3.1 South America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country
10.3.1 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Neurodegenerative Disease Treatment Market Drivers
11.2 Neurodegenerative Disease Treatment Market Restraints
11.3 Neurodegenerative Disease Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Neurodegenerative Disease Treatment Industry Chain
12.2 Neurodegenerative Disease Treatment Upstream Analysis
12.3 Neurodegenerative Disease Treatment Midstream Analysis
12.4 Neurodegenerative Disease Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Neurodegenerative Disease Treatment
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Neurodegenerative Disease Treatment by Type
1.3.1 Overview: Global Neurodegenerative Disease Treatment Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Neurodegenerative Disease Treatment Consumption Value Market Share by Type in 2022
1.3.3 Neurotransmitter Agents
1.3.4 Neuroprotective Agents
1.3.5 Biologics
1.3.6 Others
1.4 Global Neurodegenerative Disease Treatment Market by Application
1.4.1 Overview: Global Neurodegenerative Disease Treatment Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Multiple Sclerosis [MS]
1.4.3 Alzheimer’s Disease
1.4.4 Parkinson's Disease
1.4.5 Acute Migraine
1.4.6 Autism
1.4.7 Narcolepsy
1.4.8 Amyotrophic Lateral Sclerosis [ALS]
1.4.9 Attention Deficit Hyperactivity Disorder [ADHD]
1.4.10 Spinal Muscular Atrophy
1.4.11 Huntington's Disease
1.5 Global Neurodegenerative Disease Treatment Market Size & Forecast
1.6 Global Neurodegenerative Disease Treatment Market Size and Forecast by Region
1.6.1 Global Neurodegenerative Disease Treatment Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Neurodegenerative Disease Treatment Market Size by Region, (2018-2029)
1.6.3 North America Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.4 Europe Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.6 South America Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Neurodegenerative Disease Treatment Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 Allergan plc
2.1.1 Allergan plc Details
2.1.2 Allergan plc Major Business
2.1.3 Allergan plc Neurodegenerative Disease Treatment Product and Solutions
2.1.4 Allergan plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Allergan plc Recent Developments and Future Plans
2.2 Bayer AG
2.2.1 Bayer AG Details
2.2.2 Bayer AG Major Business
2.2.3 Bayer AG Neurodegenerative Disease Treatment Product and Solutions
2.2.4 Bayer AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Bayer AG Recent Developments and Future Plans
2.3 F. Hoffmann La-Roche Ltd.
2.3.1 F. Hoffmann La-Roche Ltd. Details
2.3.2 F. Hoffmann La-Roche Ltd. Major Business
2.3.3 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product and Solutions
2.3.4 F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 F. Hoffmann La-Roche Ltd. Recent Developments and Future Plans
2.4 GlaxoSmithKline plc
2.4.1 GlaxoSmithKline plc Details
2.4.2 GlaxoSmithKline plc Major Business
2.4.3 GlaxoSmithKline plc Neurodegenerative Disease Treatment Product and Solutions
2.4.4 GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Neurodegenerative Disease Treatment Product and Solutions
2.5.4 Johnson & Johnson Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 Merck KGaA
2.6.1 Merck KGaA Details
2.6.2 Merck KGaA Major Business
2.6.3 Merck KGaA Neurodegenerative Disease Treatment Product and Solutions
2.6.4 Merck KGaA Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Merck KGaA Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Neurodegenerative Disease Treatment Product and Solutions
2.7.4 Novartis AG Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Pfizer, Inc.
2.8.1 Pfizer, Inc. Details
2.8.2 Pfizer, Inc. Major Business
2.8.3 Pfizer, Inc. Neurodegenerative Disease Treatment Product and Solutions
2.8.4 Pfizer, Inc. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Pfizer, Inc. Recent Developments and Future Plans
2.9 Sanofi
2.9.1 Sanofi Details
2.9.2 Sanofi Major Business
2.9.3 Sanofi Neurodegenerative Disease Treatment Product and Solutions
2.9.4 Sanofi Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Sanofi Recent Developments and Future Plans
2.10 Teva Pharmaceutical Industries Ltd.
2.10.1 Teva Pharmaceutical Industries Ltd. Details
2.10.2 Teva Pharmaceutical Industries Ltd. Major Business
2.10.3 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product and Solutions
2.10.4 Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Neurodegenerative Disease Treatment Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Neurodegenerative Disease Treatment by Company Revenue
3.2.2 Top 3 Neurodegenerative Disease Treatment Players Market Share in 2022
3.2.3 Top 6 Neurodegenerative Disease Treatment Players Market Share in 2022
3.3 Neurodegenerative Disease Treatment Market: Overall Company Footprint Analysis
3.3.1 Neurodegenerative Disease Treatment Market: Region Footprint
3.3.2 Neurodegenerative Disease Treatment Market: Company Product Type Footprint
3.3.3 Neurodegenerative Disease Treatment Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Neurodegenerative Disease Treatment Consumption Value and Market Share by Type (2018-2023)
4.2 Global Neurodegenerative Disease Treatment Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2023)
5.2 Global Neurodegenerative Disease Treatment Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
6.2 North America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
6.3 North America Neurodegenerative Disease Treatment Market Size by Country
6.3.1 North America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
6.3.2 United States Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
6.3.3 Canada Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
6.3.4 Mexico Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
7.2 Europe Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
7.3 Europe Neurodegenerative Disease Treatment Market Size by Country
7.3.1 Europe Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
7.3.2 Germany Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.3 France Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.5 Russia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
7.3.6 Italy Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Neurodegenerative Disease Treatment Market Size by Region
8.3.1 Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2018-2029)
8.3.2 China Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.3 Japan Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.4 South Korea Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.5 India Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
8.3.7 Australia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
9.2 South America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
9.3 South America Neurodegenerative Disease Treatment Market Size by Country
9.3.1 South America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
9.3.2 Brazil Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
9.3.3 Argentina Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Neurodegenerative Disease Treatment Market Size by Country
10.3.1 Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2018-2029)
10.3.2 Turkey Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
10.3.4 UAE Neurodegenerative Disease Treatment Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Neurodegenerative Disease Treatment Market Drivers
11.2 Neurodegenerative Disease Treatment Market Restraints
11.3 Neurodegenerative Disease Treatment Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 INDUSTRY CHAIN ANALYSIS
12.1 Neurodegenerative Disease Treatment Industry Chain
12.2 Neurodegenerative Disease Treatment Upstream Analysis
12.3 Neurodegenerative Disease Treatment Midstream Analysis
12.4 Neurodegenerative Disease Treatment Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Neurodegenerative Disease Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Neurodegenerative Disease Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Neurodegenerative Disease Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Allergan plc Company Information, Head Office, and Major Competitors
Table 6. Allergan plc Major Business
Table 7. Allergan plc Neurodegenerative Disease Treatment Product and Solutions
Table 8. Allergan plc Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Allergan plc Recent Developments and Future Plans
Table 10. Bayer AG Company Information, Head Office, and Major Competitors
Table 11. Bayer AG Major Business
Table 12. Bayer AG Neurodegenerative Disease Treatment Product and Solutions
Table 13. Bayer AG Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Bayer AG Recent Developments and Future Plans
Table 15. F. Hoffmann La-Roche Ltd. Company Information, Head Office, and Major Competitors
Table 16. F. Hoffmann La-Roche Ltd. Major Business
Table 17. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product and Solutions
Table 18. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. F. Hoffmann La-Roche Ltd. Recent Developments and Future Plans
Table 20. GlaxoSmithKline plc Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline plc Major Business
Table 22. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product and Solutions
Table 23. GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. GlaxoSmithKline plc Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Neurodegenerative Disease Treatment Product and Solutions
Table 28. Johnson & Johnson Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Merck KGaA Company Information, Head Office, and Major Competitors
Table 31. Merck KGaA Major Business
Table 32. Merck KGaA Neurodegenerative Disease Treatment Product and Solutions
Table 33. Merck KGaA Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Merck KGaA Recent Developments and Future Plans
Table 35. Novartis AG Company Information, Head Office, and Major Competitors
Table 36. Novartis AG Major Business
Table 37. Novartis AG Neurodegenerative Disease Treatment Product and Solutions
Table 38. Novartis AG Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis AG Recent Developments and Future Plans
Table 40. Pfizer, Inc. Company Information, Head Office, and Major Competitors
Table 41. Pfizer, Inc. Major Business
Table 42. Pfizer, Inc. Neurodegenerative Disease Treatment Product and Solutions
Table 43. Pfizer, Inc. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Pfizer, Inc. Recent Developments and Future Plans
Table 45. Sanofi Company Information, Head Office, and Major Competitors
Table 46. Sanofi Major Business
Table 47. Sanofi Neurodegenerative Disease Treatment Product and Solutions
Table 48. Sanofi Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sanofi Recent Developments and Future Plans
Table 50. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 51. Teva Pharmaceutical Industries Ltd. Major Business
Table 52. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product and Solutions
Table 53. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 55. Global Neurodegenerative Disease Treatment Revenue (USD Million) by Players (2018-2023)
Table 56. Global Neurodegenerative Disease Treatment Revenue Share by Players (2018-2023)
Table 57. Breakdown of Neurodegenerative Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Neurodegenerative Disease Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Neurodegenerative Disease Treatment Players
Table 60. Neurodegenerative Disease Treatment Market: Company Product Type Footprint
Table 61. Neurodegenerative Disease Treatment Market: Company Product Application Footprint
Table 62. Neurodegenerative Disease Treatment New Market Entrants and Barriers to Market Entry
Table 63. Neurodegenerative Disease Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Neurodegenerative Disease Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Neurodegenerative Disease Treatment Consumption Value Share by Type (2018-2023)
Table 66. Global Neurodegenerative Disease Treatment Consumption Value Forecast by Type (2024-2029)
Table 67. Global Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023)
Table 68. Global Neurodegenerative Disease Treatment Consumption Value Forecast by Application (2024-2029)
Table 69. North America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Neurodegenerative Disease Treatment Raw Material
Table 100. Key Suppliers of Neurodegenerative Disease Treatment Raw Materials
Table 1. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Neurodegenerative Disease Treatment Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Neurodegenerative Disease Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Neurodegenerative Disease Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Allergan plc Company Information, Head Office, and Major Competitors
Table 6. Allergan plc Major Business
Table 7. Allergan plc Neurodegenerative Disease Treatment Product and Solutions
Table 8. Allergan plc Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Allergan plc Recent Developments and Future Plans
Table 10. Bayer AG Company Information, Head Office, and Major Competitors
Table 11. Bayer AG Major Business
Table 12. Bayer AG Neurodegenerative Disease Treatment Product and Solutions
Table 13. Bayer AG Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Bayer AG Recent Developments and Future Plans
Table 15. F. Hoffmann La-Roche Ltd. Company Information, Head Office, and Major Competitors
Table 16. F. Hoffmann La-Roche Ltd. Major Business
Table 17. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Product and Solutions
Table 18. F. Hoffmann La-Roche Ltd. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. F. Hoffmann La-Roche Ltd. Recent Developments and Future Plans
Table 20. GlaxoSmithKline plc Company Information, Head Office, and Major Competitors
Table 21. GlaxoSmithKline plc Major Business
Table 22. GlaxoSmithKline plc Neurodegenerative Disease Treatment Product and Solutions
Table 23. GlaxoSmithKline plc Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. GlaxoSmithKline plc Recent Developments and Future Plans
Table 25. Johnson & Johnson Company Information, Head Office, and Major Competitors
Table 26. Johnson & Johnson Major Business
Table 27. Johnson & Johnson Neurodegenerative Disease Treatment Product and Solutions
Table 28. Johnson & Johnson Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Johnson & Johnson Recent Developments and Future Plans
Table 30. Merck KGaA Company Information, Head Office, and Major Competitors
Table 31. Merck KGaA Major Business
Table 32. Merck KGaA Neurodegenerative Disease Treatment Product and Solutions
Table 33. Merck KGaA Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Merck KGaA Recent Developments and Future Plans
Table 35. Novartis AG Company Information, Head Office, and Major Competitors
Table 36. Novartis AG Major Business
Table 37. Novartis AG Neurodegenerative Disease Treatment Product and Solutions
Table 38. Novartis AG Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Novartis AG Recent Developments and Future Plans
Table 40. Pfizer, Inc. Company Information, Head Office, and Major Competitors
Table 41. Pfizer, Inc. Major Business
Table 42. Pfizer, Inc. Neurodegenerative Disease Treatment Product and Solutions
Table 43. Pfizer, Inc. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Pfizer, Inc. Recent Developments and Future Plans
Table 45. Sanofi Company Information, Head Office, and Major Competitors
Table 46. Sanofi Major Business
Table 47. Sanofi Neurodegenerative Disease Treatment Product and Solutions
Table 48. Sanofi Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Sanofi Recent Developments and Future Plans
Table 50. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
Table 51. Teva Pharmaceutical Industries Ltd. Major Business
Table 52. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Product and Solutions
Table 53. Teva Pharmaceutical Industries Ltd. Neurodegenerative Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
Table 55. Global Neurodegenerative Disease Treatment Revenue (USD Million) by Players (2018-2023)
Table 56. Global Neurodegenerative Disease Treatment Revenue Share by Players (2018-2023)
Table 57. Breakdown of Neurodegenerative Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in Neurodegenerative Disease Treatment, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key Neurodegenerative Disease Treatment Players
Table 60. Neurodegenerative Disease Treatment Market: Company Product Type Footprint
Table 61. Neurodegenerative Disease Treatment Market: Company Product Application Footprint
Table 62. Neurodegenerative Disease Treatment New Market Entrants and Barriers to Market Entry
Table 63. Neurodegenerative Disease Treatment Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global Neurodegenerative Disease Treatment Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global Neurodegenerative Disease Treatment Consumption Value Share by Type (2018-2023)
Table 66. Global Neurodegenerative Disease Treatment Consumption Value Forecast by Type (2024-2029)
Table 67. Global Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023)
Table 68. Global Neurodegenerative Disease Treatment Consumption Value Forecast by Application (2024-2029)
Table 69. North America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa Neurodegenerative Disease Treatment Consumption Value by Country (2024-2029) & (USD Million)
Table 99. Neurodegenerative Disease Treatment Raw Material
Table 100. Key Suppliers of Neurodegenerative Disease Treatment Raw Materials
LIST OF FIGURES
Figure 1. Neurodegenerative Disease Treatment Picture
Figure 2. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Type in 2022
Figure 4. Neurotransmitter Agents
Figure 5. Neuroprotective Agents
Figure 6. Biologics
Figure 7. Others
Figure 8. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Neurodegenerative Disease Treatment Consumption Value Market Share by Application in 2022
Figure 10. Multiple Sclerosis [MS] Picture
Figure 11. Alzheimer’s Disease Picture
Figure 12. Parkinson's Disease Picture
Figure 13. Acute Migraine Picture
Figure 14. Autism Picture
Figure 15. Narcolepsy Picture
Figure 16. Amyotrophic Lateral Sclerosis [ALS] Picture
Figure 17. Attention Deficit Hyperactivity Disorder [ADHD] Picture
Figure 18. Spinal Muscular Atrophy Picture
Figure 19. Global Neurodegenerative Disease Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 20. Global Neurodegenerative Disease Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 21. Global Market Neurodegenerative Disease Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 22. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Region in 2022
Figure 24. North America Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Neurodegenerative Disease Treatment Revenue Share by Players in 2022
Figure 30. Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 31. Global Top 3 Players Neurodegenerative Disease Treatment Market Share in 2022
Figure 32. Global Top 6 Players Neurodegenerative Disease Treatment Market Share in 2022
Figure 33. Global Neurodegenerative Disease Treatment Consumption Value Share by Type (2018-2023)
Figure 34. Global Neurodegenerative Disease Treatment Market Share Forecast by Type (2024-2029)
Figure 35. Global Neurodegenerative Disease Treatment Consumption Value Share by Application (2018-2023)
Figure 36. Global Neurodegenerative Disease Treatment Market Share Forecast by Application (2024-2029)
Figure 37. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 38. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 39. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 40. United States Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. Canada Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. Mexico Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 44. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 45. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 47. France Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 48. United Kingdom Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. Russia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. Italy Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 55. Japan Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 56. South Korea Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 57. India Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Southeast Asia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 59. Australia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 60. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 61. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 62. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Argentina Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 66. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 67. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 68. Turkey Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 69. Saudi Arabia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 70. UAE Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 71. Neurodegenerative Disease Treatment Market Drivers
Figure 72. Neurodegenerative Disease Treatment Market Restraints
Figure 73. Neurodegenerative Disease Treatment Market Trends
Figure 74. Porters Five Forces Analysis
Figure 75. Manufacturing Cost Structure Analysis of Neurodegenerative Disease Treatment in 2022
Figure 76. Manufacturing Process Analysis of Neurodegenerative Disease Treatment
Figure 77. Neurodegenerative Disease Treatment Industrial Chain
Figure 78. Methodology
Figure 79. Research Process and Data Source
Figure 1. Neurodegenerative Disease Treatment Picture
Figure 2. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Type in 2022
Figure 4. Neurotransmitter Agents
Figure 5. Neuroprotective Agents
Figure 6. Biologics
Figure 7. Others
Figure 8. Global Neurodegenerative Disease Treatment Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Neurodegenerative Disease Treatment Consumption Value Market Share by Application in 2022
Figure 10. Multiple Sclerosis [MS] Picture
Figure 11. Alzheimer’s Disease Picture
Figure 12. Parkinson's Disease Picture
Figure 13. Acute Migraine Picture
Figure 14. Autism Picture
Figure 15. Narcolepsy Picture
Figure 16. Amyotrophic Lateral Sclerosis [ALS] Picture
Figure 17. Attention Deficit Hyperactivity Disorder [ADHD] Picture
Figure 18. Spinal Muscular Atrophy Picture
Figure 19. Global Neurodegenerative Disease Treatment Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 20. Global Neurodegenerative Disease Treatment Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 21. Global Market Neurodegenerative Disease Treatment Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 22. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Region (2018-2029)
Figure 23. Global Neurodegenerative Disease Treatment Consumption Value Market Share by Region in 2022
Figure 24. North America Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 25. Europe Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 26. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 27. South America Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 28. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 29. Global Neurodegenerative Disease Treatment Revenue Share by Players in 2022
Figure 30. Neurodegenerative Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 31. Global Top 3 Players Neurodegenerative Disease Treatment Market Share in 2022
Figure 32. Global Top 6 Players Neurodegenerative Disease Treatment Market Share in 2022
Figure 33. Global Neurodegenerative Disease Treatment Consumption Value Share by Type (2018-2023)
Figure 34. Global Neurodegenerative Disease Treatment Market Share Forecast by Type (2024-2029)
Figure 35. Global Neurodegenerative Disease Treatment Consumption Value Share by Application (2018-2023)
Figure 36. Global Neurodegenerative Disease Treatment Market Share Forecast by Application (2024-2029)
Figure 37. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 38. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 39. North America Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 40. United States Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 41. Canada Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 42. Mexico Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 43. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 44. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 45. Europe Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 46. Germany Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 47. France Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 48. United Kingdom Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 49. Russia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 50. Italy Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 51. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 52. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 53. Asia-Pacific Neurodegenerative Disease Treatment Consumption Value Market Share by Region (2018-2029)
Figure 54. China Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 55. Japan Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 56. South Korea Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 57. India Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 58. Southeast Asia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 59. Australia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 60. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 61. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 62. South America Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 64. Argentina Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 65. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Type (2018-2029)
Figure 66. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Application (2018-2029)
Figure 67. Middle East and Africa Neurodegenerative Disease Treatment Consumption Value Market Share by Country (2018-2029)
Figure 68. Turkey Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 69. Saudi Arabia Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 70. UAE Neurodegenerative Disease Treatment Consumption Value (2018-2029) & (USD Million)
Figure 71. Neurodegenerative Disease Treatment Market Drivers
Figure 72. Neurodegenerative Disease Treatment Market Restraints
Figure 73. Neurodegenerative Disease Treatment Market Trends
Figure 74. Porters Five Forces Analysis
Figure 75. Manufacturing Cost Structure Analysis of Neurodegenerative Disease Treatment in 2022
Figure 76. Manufacturing Process Analysis of Neurodegenerative Disease Treatment
Figure 77. Neurodegenerative Disease Treatment Industrial Chain
Figure 78. Methodology
Figure 79. Research Process and Data Source
